上海医药(601607.SH)：二羟丙茶碱注射液获得批准生产

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), has received a Drug Registration Certificate from the National Medical Products Administration for its Dihydrocodeine Injection, which has been approved for production [1] Group 1 - The Dihydrocodeine Injection is indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema [1] - The medication can also be used for alleviating symptoms caused by pulmonary edema due to heart failure [1]